Coles or Wesfarmers: What will be the effect of the demerger?

|

Published 26-NOV-2018 09:26 A.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Last week, the Australian share market had a poor start to the week, falling by around 1 per cent, following a fall on overseas markets.

The effect of this fall was felt by many on the ASX, except it seems for Coles Group (ASX:XCOL).

The demerger of COL from Wesfarmers saw the stock opening at $12.49 before trading to a high of $13.37. It closed the day at $12.75. COL is currently trading on a deferred settlement basis, with normal trading to occur from 29 November 2018.

When demergers or new listings occur, some investors attempt to make a quick return by selling the stock when there is heightened interest. Given this, it is not uncommon to see the price break up only to fall away in the days following. It is thus important for investors not to get caught up with these listings. History also dictates that there is more than a 50 per cent probability the stock will be trading below the issue price within the first 12 months.

The problem with demergers is that investors who held shares in the stock prior to it demerging are far less inclined to sell their shares after the demerger. But it is important for investors to understand that the group is demerging for a reason and, in most cases, one stock will benefit while the other will struggle. In this instance, Wesfarmers could benefit much more from the demerger – although it would be wise for investors to wait for Wesfarmers shares to stabilise and start moving up before buying given that it has fallen almost 19 per cent in recent months. That said, Wesfarmers has promising growth prospects including plenty of cash on the balance sheet to pursue acquisitions.

So what do we expect in the market?

Looking at the sectors, Information Technology (XIJ) was hit hardest last week falling around 7 per cent alongside, Energy (XEJ) which was down 4 per cent.

Since October, the Energy sector is down from its high of 12,667 points and has fallen over 20 per cent to a recent low of 9,967 points. Falling oil prices have been the catalyst for the sharp drop with the price of WTI crude oil falling from above $75 a barrel in October to below $55 a barrel this week.

Concerns over global demand and China’s economic slowdown, along with lifts in both the US and Saudi Oil production has seen price slide in recent months. There is a lot of support for Light Sweet Crude Oil around the $51.00 price level, which is a point where I think it will turn to rise.

Financials (XFJ) got a lift this week from the big 4 with CBA, Westpac, ANZ and NAB all up around 2 per cent.

Dale Gillham is Chief Analyst and founder of Wealth Within.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X